Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 10, 2009, Pages 1189-1192

  Solomon, M ^a   Baum, S ^a   Barzilai, A ^a   Pavlotsky, F ^a   Trau, H ^a   Schwartz, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Intralesional; Leishmania major; Leishmaniasis; Sodium stibogluconate

Indexed keywords

PAROMOMYCIN; STIBOGLUCONATE SODIUM;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALING; HUMAN; HYPERAMYLASEMIA; INJECTION SITE PAIN; INJECTION SITE REACTION; ISRAEL; LEISHMANIA MAJOR; LIVER TOXICITY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN LEISHMANIASIS; SOLDIER; TERTIARY HEALTH CARE; TREATMENT DURATION; URTICARIA;

ADOLESCENT; ADULT; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 70349138056     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03157.x     Document Type: Article

References (12)

1. Jaffe CL, Baneth G, Abdeen ZA, Schlein Y, Warburg A. Leishmaniasis in Israel and the Palestinian authority. Trends Parasitol 2004 20 : 328 332.
2. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997 24 : 684 703.
3. Neal R. Experimental chemotherapy. In : Peters W, Killikendrick R, eds. The Leishmaniasis in Biology and Medicine. Vol. II: Clinical Aspects and Control. New York : Academic Press, 1987 : 795 845.
4. Chance M. New developments in the chemotherapy of leishmaniasis. Ann Trop Med Parasitol 1995 89 (Suppl. 1 37 43.
5. Herwaldt BL. Leishmaniasis. Lancet 1999 354 : 1191 1199.
6. Aronson NE, Wortmann GW, Johnson SC et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis 1998 27 : 1457 1464.
7. Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006 100 : 264 269.
8. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007 57 : 335. e1 29.
9. Alkhawajah AM, Larbi E, al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997 91 : 899 905.
10. Mujtaba G, Khalid M. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. Int J Dermatol 1999 38 : 607 609.
11. Tallab TM, Bahamdam KA, Mirdad S et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 1996 35 : 594 597.
12. Solomon M, Trau H, Schwartz E. Old-World cutaneous leishmaniasis: an ancient disease in wait of new drugs. Ann Dermatol Venereol 2008 135 : 357 359.